Naz Rahman, an analyst from Maxim Group, reiterated the Buy rating on Cingulate Inc (CING – Research Report). The associated price target remains the same with $8.00. Discover outperforming ...

KANSAS CITY, Kan., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...

Cingulate Inc. (NASDAQ:CING), a micro-cap pharmaceutical company with a market value of $16.4 million specializing in the development of central nervous system (CNS) therapeutics, has announced ...

ITCM in classical series is renamed as ATCM and DTCM is renamed as BTCM in Cortex -R **Cortex-R has additional 4 word entry return stack. On procedure call, return address is pushed on to hardware ...

A research team at the Institute of Psychology of the Chinese Academy of Sciences, has revealed that parvalbumin (PV) interneurons in the primary somatosensory cortex (S1) preferentially encode ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The ARM® Cortex™-A9 processors are the latest and highest performance ARM processors implementing the full richness of the widely supported ARMv7 architecture. Designed around the most advanced, ...